Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus salivarius PS2
- Development stage
- Phase 2
- Lead developer
- Danone
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus salivarius PS2 (L. salivarius PS2) is a probiotic strain that was originally isolated from the breast milk of a healthy woman. [3, 10] It has been clinically studied for its effectiveness in the prevention and treatment of infectious mastitis in pregnant and lactating women. [1, 3] Oral administration of L. salivarius PS2 has been shown to significantly reduce the incidence of mastitis, decrease the bacterial load in breast milk, and improve associated symptoms. [1, 4] The mechanism of action is believed to involve modulation of the host's immune system, with studies showing changes in inflammatory and cell-growth-related gene expression (such as STC1, IL19, PLAUR, and IFNGR1) in breast milk cells and alterations in milk cytokine levels. [3] The strain is thought to reach the mammary gland from the digestive tract via an endogenous route. [4] A preclinical study investigating its effect on rotavirus-induced diarrhea found it to be less effective than other probiotic strains. [2]
- Other names
- Ligilactobacillus salivarius PS2
Beyond the preview
Go deeper on lactobacillus salivarius PS2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus salivarius PS2.